Immunome, Inc. (IMNM) Stock Price & How to Invest

Last updated November 2026

Short answer

Immunome (IMNM) is a clinical-stage oncology company whose story hinges on its lead drug varegacestat, a gamma secretase inhibitor now under FDA review for desmoid tumors with a decision date of April 28, 2027 and, since October 2026, under European review as well, so it trades as a binary bet on regulatory approval and commercial launch more than on current earnings. As of 20 November 2026 the shares closed at $16.08, at the bottom of their 52-week range and down about 23% in 2026, for a market value near $1.9 billion.

IMNM stock price

As of 2026-11-20, Immunome, Inc. (IMNM) last closed at $15.69, down 15.3% over the past year. Over the past 52 weeks it has traded between $15.69 and $29.83.

IMNM last close
$15.69
1 day
-5.54%
1 month
-12.83%
1 year
-15.33%
52-week range
$15.69 to $29.83
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Immunome, Inc.'s investor relations page. Walnut is informational, not investment advice.

IMNM key stats

At $15.69 on November 20, 2026, Immunome, Inc. (IMNM) has a market cap of $1.9B.

Market cap
$1.9B
Price to book
3.9
Beta
2.66

Market cap, P/E and yield are measured at the $15.69 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Immunome, Inc. (IMNM)?

The last two weeks for Immunome, Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • IMNM closed at $15.69 on November 20, 2026, down 16.4% over the past five trading days (from $18.77).
  • On November 9, 2026, Immunome, Inc. filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
  • On November 9, 2026, Immunome, Inc. filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
  • On November 10, 2026, Stifel lowered its target to $23.00 from $24.00 (Hold).
  • On November 10, 2026, Piper Sandler lowered its target to $30.00 from $33.00 (Overweight).

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

What does Immunome, Inc. (IMNM) do?

Immunome, Inc. is a Nasdaq-listed, clinical-stage targeted-oncology company developing cancer therapies. Its lead asset is varegacestat, a once-daily oral gamma secretase inhibitor for adults with progressing desmoid tumors; the company submitted a New Drug Application to the U.S. FDA in April 2026, the FDA accepted it in July 2026 with a PDUFA target action date of April 28, 2027, and the European Medicines Agency validated a marketing authorization application in October 2026, both backed by the Phase 3 RINGSIDE trial that showed an ~84% reduction in the risk of disease progression or death and a ~56% confirmed objective response rate versus ~9% for placebo. Behind that lead program sits an antibody-drug-conjugate (ADC) and radiotherapy pipeline, including IM-1021 (a ROR1 ADC), IM-3050 (a FAP-targeted radiotherapy), IM-1617, and additional preclinical candidates. IM-1617 dosed its first patient in June 2026 and IM-3050 in July 2026, and on 30 September 2026 the FDA cleared the IND for IM-1340, a potential first-in-class ADC for solid tumors, with a Phase 1 start expected by the end of 2026. Updated IM-1021 data in B-cell lymphomas is due at the ASH annual meeting on December 14, 2026; at a June 2026 data cutoff the drug had a 64% objective response rate (7 of 11) in diffuse large B-cell lymphoma.

As a pre-commercial developer, Immunome generates only minimal collaboration-related revenue (roughly $7 million in 2025, and none in the second or third quarters of 2026) against large research spending and recurring net losses, so the investment picture is not about earnings today. It is about whether varegacestat wins approval and launches successfully into a market where a rival oral therapy already exists, and whether the broader ADC engine produces additional clinical wins. The third quarter of 2026, reported on November 9, brought a net loss of about $85.8 million, or $0.76 per share, wider than the roughly $0.60 consensus, as R&D rose to about $69.5 million. Cash, equivalents and marketable securities of about $461.6 million at September 30, 2026 fund the plan into 2028, according to the company, but the equity remains a speculative, catalyst-driven biotech. The shares closed at $16.08 on 20 November 2026, down about 23% year to date and 8% over a year.

What's driving Immunome, Inc. (IMNM)?

1. Varegacestat FDA decision and launch

The NDA for varegacestat in desmoid tumors, accepted by the FDA in July 2026 with a PDUFA target action date of April 28, 2027, is the single largest driver, and the European Medicines Agency validated a parallel marketing application in October 2026. Strong Phase 3 RINGSIDE data (roughly 84% reduction in progression-or-death risk and a ~56% objective response rate) supports the filings, and additional RINGSIDE data, including patient-reported outcomes, was presented at ESMO in October 2026. An approval would turn Immunome into a commercial-stage company; consensus models about $49 million of revenue in 2027. The launch would enter a market where an approved oral competitor already exists.

2. ADC and radiotherapy pipeline

Beyond the lead drug, Immunome is building a pipeline of antibody-drug conjugates and targeted radiotherapies, including IM-1021 (ROR1 ADC), IM-3050 (FAP radiotherapy), and IM-1617. The FDA cleared the IND for IM-1340 on 30 September 2026 with a Phase 1 start expected by year-end, IM-1335 is expected to follow with an IND in late 2026, and further ADCs target INDs in 2027 and beyond. At a June 2026 cutoff, IM-1021 showed a 53% objective response rate (10 of 19) across B-cell non-Hodgkin lymphoma with five complete responses, alongside grade 3 or higher adverse events in 52% of treated patients; an updated dataset is due at ASH on December 14, 2026. Investors increasingly frame varegacestat as the beachhead and the ADC platform as the longer-term thesis.

3. Strong balance sheet and runway

Cash, equivalents and marketable securities of about $461.6 million as of September 30, 2026 give Immunome runway into 2028, per management, which reduces near-term financing pressure. That capital lets the company fund a potential commercial launch and advance multiple clinical programs at once. It does not, however, remove dilution risk if the company raises again to fund growth. Cash fell by about $58 million between June and September 2026, after about $63 million the prior quarter, and debt is small at about $11 million.

4. Desmoid tumor market opportunity

Desmoid tumors are a rare, locally aggressive soft-tissue condition with limited systemic options, giving a differentiated oral therapy a defined commercial niche. Immunome positions varegacestat on efficacy and tolerability against the incumbent. Success here could also validate the gamma secretase mechanism for adjacent indications.

What are the risks to Immunome, Inc. (IMNM)?

As a clinical-stage biotech, Immunome is exposed to substantial binary risk: the FDA could delay, restrict, or reject varegacestat, and any label or safety concern would materially reset the stock. The company has minimal product revenue and posts recurring net losses that keep growing (about $85.8 million in Q3 2026, up from $73.1 million in Q2 and $57.5 million a year earlier), so it depends on its cash balance and, potentially, future capital raises that could dilute shareholders. Even with approval, commercial uptake is uncertain because an established oral competitor already serves the desmoid market. Pipeline candidates are early and most drug programs fail in development, and IM-1021's safety profile (grade 3 or higher events in about half of treated patients) will be watched at ASH. The shares are volatile and can move sharply on single trial, regulatory, or insider-selling headlines: they fell about 45% over the three months to 20 November 2026 and closed at a 52-week low. Analyst views have diverged: Stifel initiated at Hold with a $24 target in October while William Blair initiated at Outperform, and the 15 analysts tracked by Yahoo Finance average a target near $35.

What is the Immunome, Inc. (IMNM) forecast?

15 analysts publish price targets on IMNM, averaging $35.13 as of November 2026, or +123.9% against the $15.69 share price on November 20, 2026. The published targets run from $23.00 to $40.00, a moderate spread, and the ratings split 16 buy, 1 hold, 0 sell. Over the last six months there have been 3 raises and 2 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full IMNM forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is IMNM a buy or a sell?

We give no verdict on Immunome, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Varegacestat FDA decision and launch. The NDA for varegacestat in desmoid tumors, accepted by the FDA in July 2026 with a PDUFA target action date of April 28, 2027, is the single largest driver, and the European Medicines Agency validated a parallel marketing application in October 2026. The most optimistic published target, $40.00, assumes this works close to its best case.

The case against. As a clinical-stage biotech, Immunome is exposed to substantial binary risk: the FDA could delay, restrict, or reject varegacestat, and any label or safety concern would materially reset the stock. The most pessimistic target, $23.00, is roughly what IMNM is worth if this bites instead.

Read the full bull and bear case on IMNM, including what would have to change to break either one. Walnut is not an investment adviser.

Has Immunome, Inc. (IMNM) split its stock?

No. Immunome, Inc. (IMNM) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Immunome, Inc. (IMNM) valued?

Market cap, P/E and dividend yield at today's price are in the IMNM key stats above. The business figures below come from Immunome, Inc.'s reported results as of November 2026 and change when it next reports.

  • Revenue: None in Q2 or Q3 2026; ~$7M in FY2025; 2027 consensus ~$49M
  • Cash, equivalents and marketable securities (September 2026): ~$462M, runway into 2028 per the company; debt ~$11M
  • Net loss: ~$85.8M in Q3 2026 (EPS -$0.76 vs ~-$0.60 expected); ~$283M trailing twelve months (EPS ~-$2.63)
  • R&D expense (Q3 2026): ~$69.5M, plus ~$20.9M G&A

As of November 2026: Immunome trades on pipeline expectations, not profits, so earnings multiples do not apply to a company with no current revenue and a trailing loss near $283 million. Its roughly $1.9 billion market value, down from about $2.0 billion in mid-October and $2.6 billion in July 2026, is the market's probability-weighted view of an April 2027 varegacestat approval plus the ADC pipeline, set against about $462 million of cash. Consensus expects losses of roughly $2.52 per share in 2026 and $2.59 in 2027, and analysts carry a strong buy consensus with a mean target near $35.

Who competes with Immunome, Inc. (IMNM)?

Desmoid tumor drug developers

SpringWorks Therapeutics markets nirogacestat (Ogsiveo), the first approved oral gamma secretase inhibitor for progressing desmoid tumors and the direct commercial reference point varegacestat would launch against.

Clinical-stage ADC and targeted-oncology companies

Immunome's antibody-drug-conjugate and radiotherapy pipeline competes for investor attention and clinical validation with a broad set of ADC-focused developers such as ImmunoGen-style franchises, Mersana, and other targeted-oncology biotechs advancing similar modalities.

Large-cap oncology platforms

Established oncology players including AstraZeneca, Merck, and Pfizer set the standard of care, control much of the partnering and acquisition market, and could either license, acquire, or out-compete small developers like Immunome.

What stocks are similar to Immunome, Inc. (IMNM)?

Other names that sit close to IMNM: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Immunome, Inc. (IMNM)

There are three common ways to get IMNM exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so IMNM sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where IMNM fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Immunome, Inc. (IMNM)

IMNM is a well-funded, pre-commercial cancer-drug developer whose value rides on varegacestat clearing the FDA and its ADC pipeline maturing, which makes it high-risk and event-driven, not a cash-flow story. The FDA set an April 2027 action date and the European Medicines Agency validated the marketing application in October 2026, so the approval catalysts sit about five months out; the next pipeline read is updated IM-1021 lymphoma data at ASH on December 14, 2026. The stock has fallen about 45% over three months, and cash of about $462 million at September 30, 2026 is expected to fund operations into 2028.

More on Immunome, Inc. (IMNM)

Whether IMNM is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is IMNM a buy or a sell?, and where the stock could go from here in the IMNM stock forecast.

For income investors, whether IMNM pays a dividend and how the payout looks is covered in does IMNM pay a dividend? And to weigh IMNM against a peer, read the full side-by-side comparisons: IMNM vs ADC and IMNM vs AZN.

Wondering how IMNM fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Immunome, Inc.

Ask Walnut's AI anything about IMNM and see how it fits what you own.

FAQ

What does Immunome (IMNM) do?

+

Immunome is a clinical-stage targeted-oncology company developing cancer therapies. Its lead drug, varegacestat, is under FDA review for desmoid tumors, and it also runs an antibody-drug-conjugate and radiotherapy pipeline.

Is Immunome profitable?

+

No. As a pre-commercial biotech it generates only minimal revenue (about $7 million in 2025) and posts recurring net losses, including about $85.8 million in the third quarter of 2026, when it booked no revenue, as it funds research and development.

What is varegacestat?

+

Varegacestat is Immunome's lead asset, a once-daily oral gamma secretase inhibitor for adults with progressing desmoid tumors. The company submitted a New Drug Application to the FDA in April 2026 after positive Phase 3 RINGSIDE results. The FDA accepted the application in July 2026 and set a PDUFA target action date of April 28, 2027.

How strong were the varegacestat trial results?

+

In the Phase 3 RINGSIDE trial, varegacestat showed a statistically significant benefit, with roughly an 84% reduction in the risk of disease progression or death and a confirmed objective response rate of about 56% versus about 9% for placebo.

Who competes with varegacestat?

+

The main reference point is SpringWorks Therapeutics' nirogacestat (Ogsiveo), the first approved oral gamma secretase inhibitor for progressing desmoid tumors. If approved, varegacestat would be a second oral option in that market.

How much cash does Immunome have?

+

As of September 30, 2026, Immunome reported about $461.6 million in cash, cash equivalents and marketable securities, down from about $520 million at the end of June, which management expects to fund operations into 2028. Future capital raises remain possible and could dilute existing shareholders.

Why is IMNM considered a high-risk stock?

+

Its value depends on binary events like FDA decisions and clinical trial outcomes rather than current earnings. A rejection, delay, or safety concern for varegacestat, or a failed pipeline program, could move the shares sharply, and most drug candidates fail in development.

How could someone research IMNM before investing?

+

You can review Immunome's SEC filings, FDA and clinical trial updates, cash runway, and competitive positioning against nirogacestat. Walnut is not an investment adviser, so treat this as descriptive information and do your own due diligence.

When will the FDA decide on varegacestat?

+

The FDA accepted Immunome's New Drug Application for varegacestat in desmoid tumors in July 2026 and set a PDUFA target action date of April 28, 2027. In October 2026 the European Medicines Agency validated the company's Marketing Authorization Application, which starts the European review. A PDUFA date is a target, and the FDA can act early, extend the review or decline to approve.

How did Immunome do in its latest quarter?

+

For the third quarter of 2026, reported on 9 November, Immunome booked no collaboration revenue and a net loss of about $85.8 million, or $0.76 per share, wider than the roughly $0.60 loss analysts expected. R&D expense was about $69.5 million and G&A about $20.9 million. Cash, equivalents and marketable securities stood at about $461.6 million, with runway into 2028. The release confirmed the April 28, 2027 PDUFA date and the October EMA validation.

How has IMNM stock performed in 2026?

+

IMNM closed at $16.08 on 20 November 2026, a 52-week low, down about 23% year to date and about 8% over twelve months. It traded as high as about $30 within the past year, and fell roughly 45% over the last three months and about 11% over the last month, a period that included a Hold initiation from Stifel, the EMA validation and a wider-than-expected third quarter loss. Walnut is not an investment adviser, and past performance does not predict future returns.

What is IM-1021 and when is new data due?

+

IM-1021 is Immunome's ROR1-targeted antibody-drug conjugate, in a Phase 1 trial in advanced B-cell lymphomas. At a June 26, 2026 data cutoff it showed a 64% objective response rate (7 of 11) in diffuse large B-cell lymphoma and 53% (10 of 19) across B-cell non-Hodgkin lymphoma, with grade 3 or higher adverse events in 52% of 25 treated patients. An updated dataset is scheduled for the ASH annual meeting on December 14, 2026.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Immunome, Inc.'s investor relations page or your broker before making investment decisions.